Ovarian Endometrioid Adenocarcinoma (DBCOND0028505)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00719303	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	No drug interventions	prevention	3	unknown_status
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Bevacizumab Sapanisertib	treatment	1	active_not_recruiting
NCT00004221	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer	Carboplatin Cyclophosphamide Filgrastim Paclitaxel Topotecan	treatment	2	terminated
NCT01080521	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT03641287	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	No drug interventions	supportive_care	Not Available	terminated
NCT05498597	AMT-151 in Patients With Selected Advanced Solid Tumours	No drug interventions	treatment	1	recruiting
NCT01074411	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bortezomib Bortezomib D-mannitol Carboplatin	treatment	1	completed
NCT01294293	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Doxorubicin Motolimod Paclitaxel	treatment	1	completed
NCT01489371	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Cholesterol Doxorubicin EGEN-001 Tetracycline	treatment	1	completed
NCT00939809	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Urokinase	treatment	2	completed
NCT00888615	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Elesclomol Paclitaxel	treatment	2	completed
NCT00002913	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer	Cisplatin Filgrastim Paclitaxel Topotecan	treatment	1	completed
NCT00993616	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	Belinostat Carboplatin	treatment	2	completed
NCT00951496	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bevacizumab Carboplatin Chloride ion Cisplatin Paclitaxel Platinum	treatment	3	completed
NCT00028496	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Sargramostim	treatment	1	completed
NCT02283658	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Everolimus Letrozole	treatment	2	completed
NCT02713386	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Paclitaxel Ruxolitinib	treatment	1 / 2	unknown_status
NCT02923739	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Emactuzumab Paclitaxel	treatment	2	terminated
NCT00079430	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	1	completed
NCT00357448	Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer	Denileukin diftitox Human interleukin-2	treatment	1	completed
NCT01504126	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Propranolol	treatment	0	completed
NCT01010126	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Bevacizumab Menthol Sirolimus Temsirolimus	treatment	2	completed
NCT01492920	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	No drug interventions	supportive_care	3	withdrawn
NCT01459380	Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Bevacizumab Carboplatin Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT03648489	Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Paclitaxel Sapanisertib	treatment	2	unknown_status
NCT01097746	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	2	completed
NCT01167712	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	3	active_not_recruiting
NCT05950464	Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer	Tuvusertib	treatment	1	recruiting
NCT01275664	Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer	Aprepitant Carboplatin Chloride ion Cisplatin Dexamethasone Granisetron Platinum	supportive_care	Not Available	terminated
NCT00059787	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma	Carboplatin Erlotinib Paclitaxel	treatment	2	completed
NCT00989651	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Carboplatin Chloride ion Cisplatin Paclitaxel Platinum Veliparib	treatment	1	completed
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Docetaxel Gemcitabine Paclitaxel	treatment	3	active_not_recruiting
NCT00262847	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	3	completed
NCT03924245	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Entinostat Olaparib	treatment	1	terminated
NCT00108745	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Glutamic acid Paclitaxel Paclitaxel poliglumex	treatment	3	unknown_status
NCT03587311	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Anetumab ravtansine Bevacizumab Paclitaxel	treatment	2	active_not_recruiting
NCT05226507	A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer	No drug interventions	treatment	1	recruiting
NCT02020707	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	Albumin human Bevacizumab Paclitaxel	treatment	1	completed
NCT05415709	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer	Carboplatin Chloride ion Cisplatin Paclitaxel Platinum	treatment	0	recruiting
NCT02122185	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Metformin	treatment	2	active_not_recruiting
NCT00060359	Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer	Carboplatin Glutamic acid Paclitaxel poliglumex	treatment	1	completed
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Adavosertib Gemcitabine	treatment	2	active_not_recruiting
NCT02364713	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	Bevacizumab Doxorubicin Gemcitabine Measles virus vaccine live attenuated Paclitaxel Sodium iodide Tetracycline Topotecan	treatment	2	active_not_recruiting
NCT02853318	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Cyclophosphamide Pembrolizumab	treatment	2	completed
NCT02111941	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Folic acid	treatment	0	active_not_recruiting
NCT00085358	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)	Bevacizumab Carboplatin Docetaxel Paclitaxel	treatment	1	completed
NCT04575935	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial	No drug interventions	treatment	3	recruiting
NCT04611139	Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers	Pembrolizumab Seclidemstat	treatment	1	withdrawn
NCT01116648	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Cediranib Olaparib	treatment	1 / 2	active_not_recruiting
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	Cediranib Doxorubicin Olaparib Paclitaxel Tetracycline Topotecan	treatment	2 / 3	active_not_recruiting
NCT05276973	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	Carboplatin Ipatasertib Paclitaxel	treatment	1	recruiting
NCT00466960	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy	Albumin human Paclitaxel Sargramostim	treatment	2	completed
NCT02068794	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Measles virus vaccine live attenuated Sodium iodide	treatment	1 / 2	active_not_recruiting
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Bevacizumab Pegcetacoplan Pembrolizumab	treatment	2	recruiting